Comparative Pharmacology
Head-to-head clinical analysis: PHERAZINE DM versus TESSALON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHERAZINE DM versus TESSALON.
PHERAZINE DM vs TESSALON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phererazine DM is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic properties) and dextromethorphan (a non-opioid antitussive that acts on the sigma-1 receptor and NMDA receptor antagonist). Promethazine blocks H1 receptors and reduces histamine-mediated symptoms, while dextromethorphan suppresses cough by central action on the cough center.
Benzonatate is a local anesthetic structurally related to tetracaine that inhibits pulmonary stretch receptors and reduces the cough reflex by decreasing the sensitivity of vagal afferent fibers in the respiratory tract.
Adults: 1 tablet (promethazine 25 mg / dextromethorphan 30 mg) orally every 6-8 hours as needed; maximum 4 tablets per day.
100 mg orally three times daily as needed for cough. Maximum 600 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in children; 5-6 hours in adults; up to 8 hours in elderly. Clinical context: Dosing interval adjustment needed in renal impairment.
Terminal elimination half-life is approximately 12-15 hours in adults; significant interindividual variability. No accumulation with q6h dosing.
Primarily renal: 60-70% as unchanged drug and glucuronide conjugate; 15-20% fecal via biliary excretion.
Renal: <5% unchanged; primary route is hepatic metabolism with metabolites excreted renally and fecally; exact biliary/fecal % not established in humans.
Category C
Category C
Antitussive/Antihistamine Combination
Antitussive